1. Home
  2. SDHC vs KZIA Comparison

SDHC vs KZIA Comparison

Compare SDHC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith Douglas Homes Corp.

SDHC

Smith Douglas Homes Corp.

HOLD

Current Price

$13.16

Market Cap

102.3M

Sector

N/A

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$13.91

Market Cap

100.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDHC
KZIA
Founded
2008
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.3M
100.8M
IPO Year
2023
2002

Fundamental Metrics

Financial Performance
Metric
SDHC
KZIA
Price
$13.16
$13.91
Analyst Decision
Hold
Strong Buy
Analyst Count
6
4
Target Price
$14.60
$19.50
AVG Volume (30 Days)
77.6K
274.9K
Earning Date
04-29-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$971,116,000.00
N/A
Revenue This Year
$4.21
N/A
Revenue Next Year
$11.07
N/A
P/E Ratio
$216.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.13
$3.05
52 Week High
$23.50
$17.40

Technical Indicators

Market Signals
Indicator
SDHC
KZIA
Relative Strength Index (RSI) 43.05 72.60
Support Level $11.18 $5.85
Resistance Level $15.45 $14.42
Average True Range (ATR) 0.90 1.23
MACD -0.13 0.16
Stochastic Oscillator 16.37 89.23

Price Performance

Historical Comparison
SDHC
KZIA

About SDHC Smith Douglas Homes Corp.

Smith Douglas Homes Corpis a builder of single-family homes in communities in certain markets in the southeastern and southern United States. The Company's homes and communities are targeted to first-time and empty-nest homebuyers. The Company currently operates in metropolitan Atlanta, Birmingham, Chattanooga, Central Georgia, Charlotte, Dallas-Fort Worth, Greenville, Alabama Gulf Coast, Huntsville, Nashville, Raleigh and Houston. Its operations are currently organized into ten geographical divisions which comprise two reportable segments. Its Southeast segment consists of its Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of its Alabama, Dallas-Fort Worth, Houston, Nashville, and Alabama Gulf Coast divisions.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: